Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care

Official title

Stereotactic Radiation Therapy for Oligometastasis (1-5) in Various Tumor Sites in Comparison to Palliative Care of Oligometastatic Tumors.

Overview

Currently, the usual standard of palliative treatment used in patients with diagnosed oligometastatic cancer in accordance with the local clinical recommendations is chemotherapy and/or a symptomatic course of radiation therapy in doses less than ablative ones The aim of the study is to increase the effectiveness of treatment of patients with tumors of various localizations with oligometastases in the bones and internal organs with the help of stereotactic radiation therapy. The method of stereotactic radiation therapy will be applied in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy treatment T1-4, N0-3, M0-1, over 18 years of age at the start of treatment, compared with standard methods of palliative therapy in those same patient models.

Detailed description

1\. A patient with a previously verified diagnosis of a malignant neoplasm of one of the localizations (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64) who meets the inclusion criteria, after randomization by random numbers into the study group, is carried out:

1. 3-dimensional/4-dimensional computed tomography for simulation using specialized fixation devices (the choice of the method of computed tomography and fixing devices will be carried out depending on the location of the metastasis). 2. The resulting images are added to the contouring program. 3. Delineation of targets and risk organs is performed. 4. The clinical volumes and margins for the errors are determined. 5. Prescribing the total dose per target and dose limits for critical structures. 6. Dosimetric planning of the course of external-beam radiation therapy is carried out. 7. Irradiation sessions are carried out on a linear accelerator with a multi-leaf collimator, with the presence of a function for visual control of the target using cone tomography with a kilo-voltage/mega-voltage beam. 8. When the target is localized in the lungs, liver, and adrenal glands, in order to reduce the radiation load on the surrounding healthy tissues and achieve the necessary control over the position of metastasis, irradiation is carried out with a deep breath hold, or at certain phases of respiration.

Tumor localization / Description /Total focal dose, Gy/ Number of fractions /Single focal dose, Gy/ Irradiation mode:

Lung Tumors:

1. of 3cm or less located in the parenchyma TD45Gy in 3Fx with 15Gy every day 2. adjacent to the chest wall or less than 3 cm TD50Gy in 5Fx with 10Gy every day 3. within 2 cm of the mediastinum or brachial plexus TD60Gy in 8Fx with 7.5Gy every day

Bones TD24Gy in 3Fx with 8Gy every day

Brain Metastasis

1. volume from 0.5 to 5 cm3 TD20-22Gy in 1Fx at a time 2. volume of metastasis is from 5 to 10 cm3 TD16-18Gy or TD18-20Gy in 1 Fx at a time

Liver Radiation regimen selection based on tolerance of surrounding tissues and diligence to critical structures TD30-60Gy in 3-8Fx with 6-15Gy every day

Adrenal Glands TD60Gy in 8Fx with 7.5Gy every day

2\. The expected duration of the patient's participation in clinical testing, a description of the sequence and duration of all periods of clinical testing, including the period of follow-up, if any;

Periods of clinical testing:

* pre-hospital (includes a comprehensive examination of the patient before treatment) * inpatient (includes pre-radiation training for up to 3 working days, remote radiation therapy, from one to eight working days); * follow-up - after 3, 6, 9, 12, 18, 24 months; * collection and processing of the received data.

Interventions

• Radiation stereotactic ablative radiation therapy
  stereotactic ablative radiation therapy in effective doses to each metastatic site
• Radiation palliative radiation therapy
  palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)
• Drug Chemotherapy
  prescribed drug line

Primary outcome measures

• Progression-free survival [Time frame: At approximately end of year 1, 2,3 (study completion)]
• Time before the current drug line change [Time frame: At approximately the end of years 1, 2, 3 (study completion)]

Secondary outcome measures (5)

• Acute side effects [Time frame: At approximately the end of months 1, 2, 3 (treatment completion)]
• Late side effects [Time frame: At approximately the end of years 1, 2, 3 (study completion)]
• Overall survival [Time frame: At approximately the end of years 1, 2, 3 (study completion)]
• Local metastasis control [Time frame: At approximately the end of years 1, 2, 3 (study completion)]
• Quality of life Assessed with the Functional Assessment via EQ-5D (EuroQolGroup Scale) and The Numerical Rating Pain Scale [Time frame: At approximately the end of month 1, 2, 3, 6, 12 (study completion)]

Eligibility criteria

Inclusion criteria

• Histologically confirmed malignant formation (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64).
• 0-2 points on the WHO/ECOG scale of assessment of the general condition of the patient.
• The absence of disease progression after the current line of chemotherapeutic treatment.
• The number of oligometastases is not more than 3 in one organ, in the presence of a multi-organ lesion.
• The total number of distant metastases is no more than 5.
• Life expectancy of more than 6 months for brain metastases (GPA-score)
• The possibility of SBRT for all distant metastases, in accordance with the criteria specified in the study design.
• Making decisions on the inclusion of a patient in the study protocol based on the results of an interdisciplinary consultation consisting of an oncologist, a chemotherapist and a radiotherapist.
• Signed informed consent

Exclusion criteria

• 3-4 points on the WHO/ECOG scale of assessment of the general condition of the patient
• The complete response of all foci to the chemotherapy.
• Distant metastases only in the brain, without damage to bones and other organs.
• Brain metastasis of more than 3 cm in one dimension, requiring surgical treatment.
• Distant metastasis in the brain stem and spinal cord.
• The size of at least one distant metastasis is more than 5 cm.
• Previously performed radiation therapy on one of the metastatic foci.
• Metastatic lesion of the pleura, membranes of the brain or peritoneum.
• The impossibility of CTT for all distant metastases, in accordance with the criteria specified in the study design.
• Invasion into great vessels (aorta, carotid arteries, pulmonary arteries, etc.), organs of the digestive tract (esophagus, stomach, intestines), skin.
• Compression of the spinal cord by distant metastasis according to instrumental studies.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Treatment

Study locations

Russia · 1 center

• A. Tsyb Medical Radiological Research Center — Obninsk

Identifiers

NCT: NCT06556550 · 2024_40_3

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗